
Sandra Ribeiro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5296451/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk Factors for Mortality in Hemodialysis Patients: Two-Year Follow-Up Study. Disease Markers, 2013, 35, 791-798.	0.6	45
2	Iron-Hepcidin Dysmetabolism, Anemia and Renal Hypoxia, Inflammation and Fibrosis in the Remnant Kidney Rat Model. PLoS ONE, 2015, 10, e0124048.	1.1	33
3	Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations. Disease Markers, 2013, 35, 85-96.	0.6	32
4	Iron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Reviews, 2016, 30, 65-72.	2.8	28
5	Oxidized lowâ€density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: Influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene. Hemodialysis International, 2012, 16, 481-490.	0.4	21
6	Main Determinants of PON1 Activity in Hemodialysis Patients. American Journal of Nephrology, 2012, 36, 317-323.	1.4	16
7	Hepcidin in chronic kidney disease anemia. Vitamins and Hormones, 2019, 110, 243-264.	0.7	14
8	Potential Cardiovascular Risk Protection of Bilirubin in End-Stage Renal Disease Patients under Hemodialysis. BioMed Research International, 2014, 2014, 1-9.	0.9	12
9	Circulating cell-free DNA levels in hemodialysis patients and its association with inflammation, iron metabolism, and rhEPO doses. Hemodialysis International, 2013, 17, n/a-n/a.	0.4	11
10	Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia. International Journal of Molecular Sciences, 2016, 17, 28.	1.8	11
11	Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia. Biochimie, 2016, 125, 150-162.	1.3	11
12	Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients. Renal Failure, 2013, 35, 1392-1398.	0.8	10
13	Renal riskâ€benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model – hypertension, anaemia, inflammation and drug dose. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 343-354.	0.9	10
14	Liver iron is a major regulator of hepcidin gene expression via <scp>BMP/SMAD</scp> pathway in a rat model of chronic renal failure under treatment with high r <scp>H</scp> u <scp>EPO</scp> doses. BioFactors, 2016, 42, 296-306.	2.6	8
15	Recombinant human erythropoietin-induced erythropoiesis regulates hepcidin expression over iron status in the rat. Blood Cells, Molecules, and Diseases, 2016, 59, 63-70.	0.6	6
16	Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients. Renal Failure, 2012, 34, 1355-1358.	0.8	4
17	Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sciences, 2016, 151, 147-156.	2.0	4
18	Vascular Access versus the Effect of Statins on Inflammation and Fibrinolysis in Renal Dialysis Patients. Journal of Vascular Access, 2013, 14, 335-341.	0.5	3

SANDRA RIBEIRO

#	Article	IF	CITATIONS
19	Influence of the 6-month physical activity programs on renal function in obese boys. Pediatric Research, 2018, 83, 1011-1015.	1.1	3
20	Comparison of Bio-Plex measurements with standard techniques. Clinical Chemistry and Laboratory Medicine, 2012, 50, 399-402.	1.4	1
21	Adiponectin is an independent predictor of tissue plasminogen activator levels in patients under haemodialysis . Scandinavian Journal of Urology and Nephrology, 2012, 46, 461-465.	1.4	1
22	SP313LIVER IRON IS A MAJOR REGULATOR OF HEPCIDIN GENE EXPRESSION VIA BMP/SMAD PATHWAY IN A RAT MODEL OF CHRONIC RENAL FAILURE UNDER TREATMENT WITH HIGH rHuEPO DOSES. Nephrology Dialysis Transplantation, 2016, 31, i194-i194.	0.4	1
23	The HIF System Response to ESA Therapy in CKDâ€Anemia. , 2017, , .		0